Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [Pediatric Oncology]

Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort from pooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Rhabdomyosarcoma & Soft Tissue Sarcoma, Chemotherapy, Rhabdo & Other Soft Tissue Sarcomas: Pediatric Oncology Source Type: research